A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide, followed by a 4 week double-blind, randomized, placebo-controlled withdrawal in patients with essential hypertension.

Trial Profile

A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide, followed by a 4 week double-blind, randomized, placebo-controlled withdrawal in patients with essential hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs Aliskiren (Primary) ; Ramipril (Primary)
  • Indications Essential hypertension; Hypertension
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Nov 2011 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Actual initiation date (Feb 2005) added as reported by ClinicalTrials.gov.
    • 15 May 2008 Results of a post hoc subgroup analysis of data from patients with stage 2 hypertension were presented at the 23rd annual meeting of the American Society of Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top